Latest Erbitux news
Addition of Cetuximab to CRT Cuts Locoregional Failure in Anal CA
by modernClinician Editorial Team
Addition of cetuximab to chemoradiation is associated with a reduction in locoregional failure rates in squamous cell carcinoma of the anal canal, according to a study published online Jan. 9 in the Journal of Clinical Oncology.
Cetuximab + Chemoradiation Can Cure HIV-Associated Anal Cancer
by modernClinician Editorial Team
Definitive chemoradiation can potentially cure HIV-associated squamous cell carcinoma of the anal canal, with the addition of cetuximab resulting in less locoregional failure, according to a study published online Dec. 12 in the Journal of Clinical Oncology.
Possible Benefit for Addition of Cetuximab to RT in Laryngeal CA
by modernClinician Editorial Team
For patients with hypopharyngeal or laryngeal carcinoma, the addition of cetuximab to radiotherapy is associated with a nonsignificant improvement in laryngeal preservation and laryngectomy-free survival, according to a study published online July 7 in JAMA Otolaryngology-Head & Neck Surgery.
Editor's Recommendations
65.8 Percent of U.S. Counties Lack Radiation Oncology Practice Site 
Hematologic Cancer Survivors Face Higher Risk of Developing Cardiovascular Disease 
Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer 
Comparable Progression Risk Seen With Ablation Versus Surgery for T1a Renal Cell Carcinoma Related Articles
Full, Limited Functional Endoscopic Sinus Surgery Beneficial in Rhinosinusitis With Nasal Polyps 
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis 
Seniors Undergoing High-Risk Emergency General Surgery Have Fewer Healthy Days at Home 
Lung Transplant Can Prolong Survival in Stage IV NSCLC Monthly Specialist Briefings
Stay Connected
